Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation
Prisma Health-Upstate
Prisma Health-Upstate
M.D. Anderson Cancer Center
Zhejiang University
Royal Marsden NHS Foundation Trust
University of Pittsburgh
Dana-Farber Cancer Institute
Gustave Roussy, Cancer Campus, Grand Paris
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center
Jewish General Hospital
NuCana plc
Mayo Clinic
University of Southern California
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
Mayo Clinic
NRG Oncology
Mayo Clinic
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Swiss Cancer Institute
Thunder Bay Regional Health Research Institute
University of California, San Diego
University of Chicago
Mayo Clinic
Memorial Sloan Kettering Cancer Center
Hoosier Cancer Research Network
Capital Medical University
Dana-Farber Cancer Institute
Georgetown University
Shanghai East Hospital
University of California, Davis
Shanghai Junshi Bioscience Co., Ltd.
Shanghai Junshi Bioscience Co., Ltd.
University of Maryland, Baltimore
Rutgers, The State University of New Jersey
Henry Ford Health System
Rijnstate Hospital
University of Southern California
Roswell Park Cancer Institute
Centre Leon Berard
Augusta University
Radboud University Medical Center
Baylor College of Medicine
Mayo Clinic
Fred Hutchinson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Burzynski Research Institute
Centre Hospitalier Universitaire Vaudois
Barbara Ann Karmanos Cancer Institute
Children's Hospital Medical Center, Cincinnati